-
1Academic Journal
Authors: A. A. Burov, V. V. Zubkov, А. А. Буров, В. В. Зубков
Source: PULMONOLOGIYA; Том 34, № 3 (2024); 340-349 ; Пульмонология; Том 34, № 3 (2024); 340-349 ; 2541-9617 ; 0869-0189
Subject Terms: новорожденные, chronic neonatal pulmonary hypertension, nitric oxide (NO), persistent pulmonary hypertension of newborns (PPHN), bronchopulmonary dysplasia, premature newborns, newborns, хроническая неонатальная легочная гипертензия, оксид азота, персистирующая легочная гипертензия новорожденных, бронхолегочная дисплазия, недоношенные новорожденные
File Description: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/4557/3657; Абдулатипова И.В., Белкина М.В., Белозеров Ю.М. и др. Легочная гипертензия у детей: руководство. М.: Актелион Фармасьютикалз; 2013.; Министерство здравоохранения Российской Федерации. Клинические рекомендации. Легочная гипертензия у детей. М.; 2017. Доступно на: https://cr.minzdrav.gov.ru/recomend/31_1?ysclid=lwumvccw7r222227221; Ruoss J.L., Rios D.R., Levy P.T. Updates on management for acute and chronic phenotypes of neonatal pulmonary hypertension. Clin. Perinatol. 2020; 47 (3): 593–615. DOI:10.1016/j.clp.2020.05.006.; Буров А.А., Пруткин М.Е., Гребенников В.А. и др. Проект клинического протокола по диагностике и терапии персистируюшей легочной гипертензии новорожденных. Неонатология: новости, мнения, обучение. 2014; (1): 145–160. Доступно на: https://www.neonatology-nmo.ru/ru/jarticles_neonat/82.html; Миклашевич И.М., Школьникова М.А., Горбачевский С.В. и др. Современная стратегия терапии легочной гипертензии у детей. Кардиоваскулярная терапия и профилактика. 2018; 17 (2): 101–124. DOI:10.15829/1728-8800-2018-2-101-124.; Буров А.А. Терапия оксидом азота в неонатологии. Неонатология: новости, мнения, обучение. 2014; (4): 73–86. Доступно на: https://www.neonatology-nmo.ru/ru/jarticles_neonat/123.html?SSr=410134d89315ffffffff27c__07e8051f0f2905-1352; Roberts J.D., Polaner D.M., Lang P., Zapol W.M. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992; 340 (8823): 818–819. DOI:10.1016/0140-6736(92)92686-a.; Kinsella J.P., Neish S.R., Shaffer E., Abman S.H. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992; 340 (8823): 819–820. DOI:10.1016/0140-6736(92)92687-b.; Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N. Engl. J. Med. 1997; 336 (9): 597–604. DOI:10.1056/NEJM199702273360901.; Clark R.H., Kueser T.J., Walker M.W. et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N. Engl. J. Med. 2000; 342 (7): 469–474. DOI:10.1056/NEJM200002173420704.; Stahlman M. Treatment of cardiovascular disorders of the newborn. Pediatr. Clin. North Am. 1964; 11 (2): 363–400. DOI:10.1016/s0031-3955(16)31554-1.; Rudolph A.M., Drorbaugh J.E., Auld P.A. et al. Studies on the circulation in the neonatal period. The circulation in the respiratory distress syndrome. Pediatrics. 1961; 27: 551–566. DOI:10.1542/peds.27.4.551.; Roberton N.R., Hallidie-Smith K.A., Davis J.A. Severe respiratory distress syndrome mimicking cyanotic heart-disease in term babies. Lancet. 1967; 2 (7526): 1108–1110. DOI:10.1016/s0140-6736(67)90616-2.; Gersony W.M., Duc G.V., Sinclair J.C. "PFC" syndrome (persistence of fetal circulation). Circulation. 1969; 40 (Suppl. 1): 3–87.; Levin D.L., Heymann M.A., Kitterman J.A. et al. Persistent pulmonary hypertension of the newborn infant. J. Pediatr. 1976; 89 (4): 626–630. DOI:10.1016/s0022-3476(76)80405-2.; Harrison M.R., de Lorimier A.A. Congenital diaphragmatic hernia. Surg. Clin. North Am. 1981; 61 (5): 1023–1035. DOI:10.1016/s0039-6109(16)42528-4.; Rudolph A.M. High pulmonary vascular resistance after birth: I. Pathophysiologic considerations and etiologic classification. Clin. Pediatr. (Phila). 1980; 19 (9): 585–590. DOI:10.1177/000992288001900902.; Mous D.S., Buscop-van Kempen M.J., Wijnen R.M.H. et al. Changes in vasoactive pathways in congenital diaphragmatic hernia associated pulmonary hypertension explain unresponsiveness to pharmacotherapy. Respir. Res. 2017; 18 (1): 187. DOI:10.1186/s12931-017-0670-2.; Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288 (5789): 373–376. DOI:10.1038/288373a0.; Cornfield D.N., Chatfield B.A., McQueston J.A. et al. Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. Am. J. Physiol. 1992; 262 (5, Pt 2): H1474–1481. DOI:10.1152/ajpheart.1992.262.5.H1474.; Abman S.H., Chatfield B.A., Hall S.L., McMurtry I.F. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am. J. Physiol. 1990; 259 (6, Pt 2): H1921–1927. DOI:10.1152/ajpheart.1990.259.6.H1921.; Abman S.H., Chatfield B.A., Rodman D.M. et al. Maturational changes in endothelium-derived relaxing factor activity of ovine pulmonary arteries in vitro. Am. J. Physiol. 1991; 260 (4, Pt 1): L280–285. DOI:10.1152/ajplung.1991.260.4.L280.; Fineman J.R., Soifer S.J., Heymann M.A. The role of pulmonary vascular endothelium in perinatal pulmonary circulatory regulation. Semin. Perinatol. 1991; 15 (1): 58–62. Available at: https://www.researchgate.net/publication/21093259_The_role_of_pulmonary_vascular_endothelium_in_perinatal_pulmonary_circulatory_regulation; Kinsella J.P., McQueston J.A., Rosenberg A.A., Abman S.H. Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation. Am. J. Physiol. 1992; 263 (3, Pt 2): H875–880. DOI:10.1152/ajpheart.1992.263.3.H875.; Kinsella J.P., Ivy D.D., Abman S.H. Ontogeny of NO activity and response to inhaled NO in the developing ovine pulmonary circulation. Am. J. Physiol. 1994; 267 (5, Pt 2): H1955–1961. DOI:10.1152/ajpheart.1994.267.5.H1955.; Shaul P.W., Afshar S., Gibson L.L. et al. Developmental changes in nitric oxide synthase isoform expression and nitric oxide production in fetal baboon lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002; 283 (6): L1192–1199. DOI:10.1152/ajplung.00112.2002.; Pepke-Zaba J., Higenbottam T.W., Dinh-Xuan A.T. et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991; 338 (8776): 1173–1174. DOI:10.1016/0140-6736(91)92033-x.; Frostell C., Fratacci M.D., Wain J.C. et al. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991; 83 (6): 2038–2047. DOI:10.1161/01.cir.83.6.2038.; Roberts J.D. Jr., Chen T.Y., Kawai N. et al. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ. Res. 1993; 72 (2): 246–254. DOI:10.1161/01.res.72.2.246.; Villamor E., Le Cras T.D., Horan M.P. et al. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am. J. Physiol. 1997; 272 (5, Pt 1): L1013–1020. DOI:10.1152/ajplung.1997.272.5.L1013.; Zayek M., Cleveland D., Morin F.C. 3rd. Treatment of persistent pulmonary hypertension in the newborn lamb by inhaled nitric oxide. J. Pediatr. 1993; 122 (5, Pt 1): 743–750. DOI:10.1016/s0022-3476(06)80020-x.; Kinsella J.P., Parker T.A., Galan H. et al. Independent and combined effects of inhaled nitric oxide, liquid perfluorochemical, and high-frequency oscillatory ventilation in premature lambs with respiratory distress syndrome. Chest. 1999; 116 (1, Suppl.): 15–16S. DOI:10.1378/chest.116.suppl_1.15s.; Rossaint R., Falke K.J., López F. et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N. Engl. J. Med. 1993; 328 (6): 399–405. DOI:10.1056/NEJM199302113280605.; Tworetzky W., Bristow J., Moore P. et al. Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet. 2001; 357 (9250): 118–120. DOI:10.1016/S0140-6736(00)03548-0.; Davidson D., Barefield E.S., Kattwinkel J. et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics. 1998; 101 (3, Pt 1): 325–334. DOI:10.1542/peds.101.3.325.; Sokol G.M., Fineberg N.S., Wright L.L., Ehrenkranz R.A. Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. Pediatr. Pulmonol. 2001; 32 (1): 14–19. DOI:10.1002/ppul.1083.; Black S.M., Heidersbach R.S., McMullan D.M. et al. Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension. Am. J. Physiol. 1999; 277 (5): H1849–1856. DOI:10.1152/ajpheart.1999.277.5.H1849.; Rawat M., Lakshminrusimha S., Vento M. Pulmonary hypertension and oxidative stress: where is the link? Semin. Fetal Neonatal Med. 2022; 27 (4): 101347. DOI:10.1016/j.siny.2022.101347.; Roberts J.D. Jr, Fineman J.R., Morin F.C. 3rd et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N. Engl. J. Med. 1997; 336 (9): 605–610. DOI:10.1056/NEJM199702273360902.; Kinsella J.P., Truog W.E., Walsh W.F. et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J. Pediatr. 1997; 131 (1, Pt 1): 55–62. DOI:10.1016/s0022-3476(97)70124-0.; Goldman A.P., Tasker R.C., Haworth S.G. et al. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics. 1996; 98 (4, Pt 1): 706–713. DOI:10.1542/peds.98.4.706.; Foubert L., Fleming B., Latimer R. et al. Safety guidelines for use of nitric oxide. Lancet. 1992; 339 (8809): 1615–1616. DOI:10.1016/0140-6736(92)91886-d.; Frostell C.G., Zapol W.M. Inhaled nitric oxide, clinical rationale and applications. Adv. Pharmacol. 1995; 34: 439–456. DOI:10.1016/s1054-3589(08)61102-3.; Van Meurs K.P., Wright L.L., Ehrenkranz R.A. et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N. Engl. J. Med. 2005; 353 (1): 13–22. DOI:10.1056/NEJMoa043927.; Van Meurs K.P., Rhine W.D., Asselin J.M., Durand D.J. Response of premature infants with severe respiratory failure to inhaled nitric oxide. Preemie NO Collaborative Group. Pediatr. Pulmonol. 1997; 24 (5): 319–323. DOI:10.1002/(sici)1099-0496(199711)24:53.0.co;2-d.; Högman M., Frostell C., Arnberg H., Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet. 1993; 341 (8861): 1664–1665. DOI:10.1016/0140-6736(93)90802-n.; Bassenge E. Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors. Eur. Heart. J. 1991; 12 (Suppl. E): 12–15. DOI:10.1093/eurheartj/12.suppl_e.12.; George T.N., Johnson K.J., Bates J.N., Segar J.L. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J. Pediatr. 1998; 132 (4): 731–734. DOI:10.1016/s0022-3476(98)70370-1.; Ward J., Motwani J., Baker N. et al. Congenital methemoglobinemia identified by pulse oximetry screening. Pediatrics. 2019; 143 (3): e20182814. DOI:10.1542/peds.2018-2814.; Bischoff A.R., Habib S., McNamara P.J., Giesinger R.E. Hemodynamic response to milrinone for refractory hypoxemia during therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy. J. Perinatol. 2021; 41 (9): 2345–2354. DOI:10.1038/s41372-021-01049-y.; James A.T., Corcoran J.D., McNamara P.J. et al. The effect of milrinone on right and left ventricular function when used as a rescue therapy for term infants with pulmonary hypertension. Cardiol. Young. 2016; 26 (1): 90–99. DOI:10.1017/S1047951114002698.; Kinsella J.P., Steinhorn R.H., Mullen M.P. et al. The left ventricle in congenital diaphragmatic hernia: Implications for the management of pulmonary hypertension. J. Pediatr. 2018; 197: 17–22. DOI:10.1016/j.jpeds.2018.02.040.; Cookson M.W., Abman S.H., Kinsella J.P., Mandell E.W. Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension. Semin. Fetal Neonatal Med. 2022; 27 (4): 101367. DOI:10.1016/j.siny.2022.101367.; Kinsella J.P., Abman S.H. Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia. J. Pediatr. 2000; 136 (6): 717–726. DOI:10.1016/S0022-3476(00)10660-2.; Clark R.H., Yoder B.A., Sell M.S. Prospective, randomized comparison of high-frequency oscillation and conventional ventilation in candidates for extracorporeal membrane oxygenation. J. Pediatr. 1994; 124 (3): 447–454. DOI:10.1016/s0022-3476(94)70374-4.; Kuluz M.A., Smith P.B., Mears S.P. et al. Preliminary observations of the use of high-frequency jet ventilation as rescue therapy in infants with congenital diaphragmatic hernia. J. Pediatr. Surg. 2010; 45 (4): 698–702. DOI:10.1016/j.jpedsurg.2009.07.025.; Lotze A., Mitchell B.R., Bulas D.I. et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in term infants study group. J. Pediatr. 1998; 132 (1): 40–47. DOI:10.1016/s0022-3476(98)70482-2.; González A., Bancalari A., Osorio W. et al. Early use of combined exogenous surfactant and inhaled nitric oxide reduces treatment failure in persistent pulmonary hypertension of the newborn: a randomized controlled trial. J. Perinatol. 2021; 41 (1): 32–38. DOI:10.1038/s41372-020-00777-x.; Cornfield D.N., Reeve H.L., Tolarova S. et al. Oxygen causes fetal pulmonary vasodilation through activation of a calcium-dependent potassium channel. Proc. Natl. Acad. Sci. USA. 1996; 93 (15): 8089–8094. DOI:10.1073/pnas.93.15.8089.; Cornfield D.N. Developmental regulation of oxygen sensing and ion channels in the pulmonary vasculature. Adv. Exp. Med. Biol. 2010; 661: 201–220. DOI:10.1007/978-1-60761-500-2_13.; Farrow K.N., Groh B.S., Schumacker P.T. et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ. Res. 2008; 102 (2): 226–233. DOI:10.1161/CIRCRESAHA.107.161463.; Giesinger R.E., McNamara P.J. Hemodynamic instability in the critically ill neonate: an approach to cardiovascular support based on disease pathophysiology. Semin. Perinatol. 2016; 40 (3): 174–188. DOI:10.1053/j.semperi.2015.12.005.; Nakanishi H., Suenaga H., Uchiyama A. et al. Persistent pulmonary hypertension of the newborn in extremely preterm infants: a Japanese cohort study. Arch. Dis. Child. Fetal Neonatal Ed. 2018; 103 (6): F554–561. DOI:10.1136/archdischild-2017-313778.; Nelin L., Kinsella J.P., Courtney S.E. et al. Use of inhaled nitric oxide in preterm vs term/near-term neonates with pulmonary hypertension: results of the PaTTerN registry study. J. Perinatol. 2022; 42 (1): 14–18. DOI:10.1038/s41372-021-01252-x.; Peliowski A., Finer N.N., Etches P.C. et al. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J. Pediatr. 1995; 126 (3): 450–453. DOI:10.1016/s0022-3476(95)70467-1.; Abman S.H., Hansmann G., Archer S.L. et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015; 132 (21): 2037–2099. DOI:10.1161/CIR.0000000000000329.; Kinsella J.P., Steinhorn R.H., Krishnan U.S. et al. Recommendations for the use of inhaled nitric oxide therapy in premature newborns with severe pulmonary hypertension. J. Pediatr. 2016; 170: 312–314. DOI:10.1016/j.jpeds.2015.11.050.; Chock V.Y., Van Meurs K.P., Hintz S.R. et al. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. Am. J. Perinatol. 2009; 26 (4): 317–322. DOI:10.1055/s-0028-1104743.; Kinsella J.P., Cutter G.R., Walsh W.F. et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N. Engl. J. Med. 2006; 355 (4): 354–364. DOI:10.1056/NEJMoa060442.; Ballard R.A., Truog W.E., Cnaan A. et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N. Engl. J. Med. 2006; 355 (4): 343–353. DOI:10.1056/NEJMoa061088.; Kinsella J.P., Walsh W.F., Bose C.L. et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet. 1999; 354 (9184): 1061–1065. DOI:10.1016/s0140-6736(99)03558-8.; Balasubramaniam V., Maxey A.M., Morgan D.B. et al. Inhaled NO restores lung structure in eNOS-deficient mice recovering from neonatal hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 291 (1): L119–127. DOI:10.1152/ajplung.00395.2005.; Tourneux P., Markham N., Seedorf G. et al. Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats. Am. J. Physiol. Lung Cell Mol. Physiol. 2009; 297 (6): L1103–1111. DOI:10.1152/ajplung.00293.2009.; Kinsella J.P., Parker T.A., Galan H. et al. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr. Res. 1997; 41 (4, Pt 1): 457–463. DOI:10.1203/00006450-199704000-00002.; Kumar P.; Committee on Fetus and Newborn; American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. Pediatrics. 2014; 133 (1): 164–170. DOI:10.1542/peds.2013-3444.; Giesinger R.E., Rios D.R., Chatmethakul T. et al. Impact of early hemodynamic screening on extremely preterm outcomes in a high-performance center. Am. J. Respir. Crit. Care Med. 2023; 208 (3): 290–300. DOI:10.1164/rccm.202212-2291OC.; Kinsella J.P., Parker T.A., Ivy D.D., Abman S.H. Noninvasive delivery of inhaled nitric oxide therapy for late pulmonary hypertension in newborn infants with congenital diaphragmatic hernia. J. Pediatr. 2003; 142 (4): 397–401. DOI:10.1067/mpd.2003.140.; Буранов С.Н., Карелин В.И., Селемир В.Д., Ширшин А.С. Аппарат для ингаляционной NO-терапии. Приборы и техника эксперимента. 2019; (5): 158–159. DOI:10.1134/S0032816219040037.; Володин Н.Н., Дегтярев Д.Н., ред. Неонатология: национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2023; Т. 1. DOI:10.33029/9704-7828-8-NNG-2023-1-752.; Володин Н.Н., Дегтярев Д.Н., ред. Неонатология: национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2023; Т. 2. DOI:10.33029/9704-7829-5-NNG-2023-1-768.; https://journal.pulmonology.ru/pulm/article/view/4557
-
2Academic Journal
Authors: A. V. Mostovoi, A. L. Karpova, I. V. Popov, L. A. Anikeeva, N. Yu. Karpov, А. В. Мостовой, А. Л. Карпова, И. В. Попов, Л. А. Аникеева, Н. Ю. Карпов
Source: Obstetrics, Gynecology and Reproduction; Vol 18, No 4 (2024); 581-595 ; Акушерство, Гинекология и Репродукция; Vol 18, No 4 (2024); 581-595 ; 2500-3194 ; 2313-7347
Subject Terms: высокочастотная осцилляторная искусственная вентиляция легких, poractant alpha, surfactant-BL, tauractant, acute neonatal distress syndrome, persistent pulmonary hypertension of newborns, high frequency oscillatory ventilation, порактант альфа, Сурфактант-БЛ, таурактант, острый неонатальный дистресс-синдром, персистирующая легочная гипертензия новорожденных
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2114/1238; https://www.gynecology.su/jour/article/view/2114/1239; Wiswell T.E., Tuggle J.M., Turner B.S. Meconium aspiration syndrome: have we made a difference? Pediatrics. 1990;85(5):715-21.; Cleary G.M., Wiswell T.E. Meconium-stained amniotic fluid and the meconium aspiration syndrome. An update. Pediatr Clin North Am. 1998;45(3):511-29. https://doi.org/10.1016/s0031-3955(05)70025-0.; Nathan L., Leveno K.J., Carmody T.J. et al. Meconium: a 1990s perspective on an old obstetric hazard. Obstet Gynecol. 1994;83(3):329-32.; Ross M.G. Meconium aspiration syndrome - more than intrapartum meconium. N Engl J Med. 2005;353(9):946-8. https://doi.org/10.1056/NEJMe058149.; Ostrea E.M., Naqvi M. The influence of gestational age on the ability of the fetus to pass meconium in utero. Clinical implications. Acta Obstet Gynecol Scand. 1982;61(3):275-7. https://doi.org/10.3109/00016348209156571.; Usher R.H., Boyd M.E., McLean F.H., Kramer M.S. Assessment of fetal risk in postdate pregnancies. Am J Obstet Gynecol. 1988;158(2):259-64. https://doi.org/10.1016/0002-9378(88)90134-2.; Dargaville P.A., Copnell B.; Australian and New Zealand Neonatal Network. The epidemiology of meconium aspiration syndrome: incidence, risk factors, therapies, and outcome. Pediatrics. 2006;117(5):1712-21. https://doi.org/10.1542/peds.2005-2215.; Velaphi S., Vidyasagar D. Intrapartum and postdelivery management of infants born to mothers with meconium-stained amniotic fluid: evidence-based recommendations. Clin Perinatol. 2006;33(1):29-42. https://doi.org/10.1016/j.clp.2005.11.014.; Ghidini A., Spong C.Y. Severe meconium aspiration syndrome is not caused by aspiration of meconium. Am J Obstet Gynecol. 2001;185(4):931-8. https://doi.org/10.1067/mob.2001.116828.; Богомазова И.М., Стрижаков А.Н., Игнатко И.В. и др. Неонатальная аспирация мекония: факторы риска и адаптация новорожденных. Акушерство, Гинекология и Репродукция. 2018;12(4):5-14. https://doi.org/10.17749/2313-7347.2018.12.4.005-014.; Singh B.S., Clark R.H., Powers R.J., Spitzer A.R. Meconium aspiration syndrome remains a significant problem in the NICU: outcomes and treatment patterns in term neonates admitted for intensive care during a ten-year period. JPerinatol. 2009;29(7):497-503. https://doi.org/10.1038/jp.2008.241.; Radiological Imaging of the Neonatal Chest. 2nd Revised Edition. Ed. V. Donoqhue. Springer, 2008. 362 p.; Goldsmith J.P. Continuous positive airway pressure and conventional mechanical ventilation in the treatment of meconium aspiration syndrome. JPerinatol. 2008;28 Suppl 3:S49-55. https://doi.org/10.1038/jp.2008.156.; Wiswell T.E., Gannon C.M., Jacob J. et al. Delivery room management of the apparently vigorous meconium-stained neonate: results of the multicenter, international collaborative trial. Pediatrics. 2000;105 (1 Pt 1):1–7. https://doi.org/10.1542/peds.105.1.1.; Bondarev V.V., Mostovoy A.V., Narimanbecov I.O. High frequency oscillatory ventilation in respiratory treatment of neonates with severe respiratory distress syndrome. The 7th Baltic Sea Congress on Obstetrics and Gynecology. Журнал акушерства и женских болезней. 1999;48(5S):45. (In English). https://doi.org/10.17816/JOWD100809.; Lin H.C., Su B.H., Lin T.W. et al. System-based strategy for the management of meconium aspiration syndrome: 198 consecutive cases observations. Acta Paediatr Taiwan. 2005;46(2):67-71.; Keszler M., Molina B., Butterfield A.B., Subramanian K.N. Combined high-frequency jet ventilation in a meconium aspiration model. Crit Care Med. 1986;14(1):34-8. https://doi.org/10.1097/00003246-198601000-00009.; Tingay D.G., Mills J.F., Morley C.J. et al.; Australian and New Zealand Neonatal Network. Trends in use and outcome of newborn infants treated with high frequency ventilation in Australia and New Zealand, 1996-2003. J Paediatr Child Health. 2007;43(3):160-6. https://doi.org/10.1111/j.1440-1754.2007.01036.x.; Мостовой А.В., Иванов С.Л., Морозов К.А. Комплексная терапия легочной гипертензии у новорожденных с применением высокочастотной осцилляторной вентиляции легких и ингаляции оксида азота. Интенсивная терапия в неонатологии. 2003;(2):49-53.; Finer N.N., Barrington K.J. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2006;(4):CD000399. https://doi.org/10.1002/14651858.CD000399.pub2.; Мостовой А.В., Карпова А.Л. Искусственная вентиляция легких у новорожденных. Физиологические особенности газообмена и механики дыхания как основа для управления параметрами вентиляции. Детские болезни сердца и сосудов. 2016;13(2):79-87.; De Luca D., van Kaam A.H., Tingay D.G. et al. The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity. Lancet Respir Med. 2017;5(8):657-66. https://doi.org/10.1016/S2213-2600(17)30214-X.; Schumacher R.E., Roloff D.W., Chapman R. et al. Extracorporeal membrane oxygenation in term newborns. A prospective cost-benefit analysis. ASAIO J. 1993;39(4):873-9.; Lakshminrusimha S., Keszler M. Persistent pulmonary hypertension of the newborn. Neoreviews. 2015;16(12):e680-e692. https://doi.org/10.1542/neo.16-12-e680.; Kugelman A., Gangitano E., Taschuk R. et al. Extracorporeal membrane oxygenation in infants with meconium aspiration syndrome: a decade of experience with venovenous ECMO. J Pediatr Surg. 2005;40(7):1082-9. https://doi.org/10.1016/j.jpedsurg.2005.03.045.; Dargaville P.A., Copnell B., Mills J.F. et al.; lessMAS Trial Study Group. Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome. J Pediatr. 2011;158(3):383-389.e2. https://doi.org/10.1016/j.jpeds.2010.08.044.; Dargaville P.A. Innovation in surfactant therapy I: surfactant lavage and surfactant administration by fluid bolus using minimally invasive techniques. Neonatology. 2012;101(4):326-36. https://doi.org/10.1159/000337346.; Hahn S., Choi H.J., Soll R., Dargaville P.A. Lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev. 2013;(4):CD003486. https://doi.org/10.1002/14651858.CD003486.pub2.; Arayici S., Sari F.N., Kadioglu Simsek G. et al. Lung lavage with dilute surfactant vs. bolus surfactant for meconium aspiration syndrome. J Trop Pediatr. 2019;65(5):491-7. https://doi.org/10.1093/tropej/fmy081.; Xu Y., Guo X., Chen M. et al. Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits. Pediatr Res. 2023;93(3):541-50. https://doi.org/10.1038/s41390-022-02152-2.; Rey-Santano C., Alvarez-Diaz F.J., Mielgo V. et al. Bronchoalveolar lavage versus bolus administration of lucinactant, a synthetic surfactant in meconium aspiration in newborn lambs. Pediatr Pulmonol. 2011t;46(10):991-9. https://doi.org/10.1002/ppul.21460.; Инструкция по медицинскому применению лекарственного препарата Сурфактант-БЛ. М.: Министерство здравоохранения Российской Федерации, 2021. 21 с. Режим доступа: https://biosurf.ru/upload/iblock/c9f/c9fdfc8dc57585fcc4e53d6b0eed8fb3.pdf. [Дата обращения: 09.05.2024].; Виноградова И.В., Никифорова Г.И. Применение сурфактанта БЛ у новорожденных с синдромом аспирации мекония. Российский вестник перинатологии и педиатрии. 2011;(4):15-9.; Hui R., Jing-Jing P., Yun-Su Z. et al. Surfactant lavage for neonatal meconium aspiration syndrome-An updated meta-analysis. J Chin Med Assoc. 2020;83(8):761-73. https://doi.org/10.1097/JCMA.0000000000000357.; Lam B.C., Yeung C.Y. Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics. 1999;103(5 Pt 1):1014-8. https://doi.org/10.1542/peds.103.5.1014.; Kowalska K, Szymankiewicz M, Gadzinowski J. Aneffectiveness of surfactant lung lavage (SLL) in meconium aspiration syndrome (MAS). Przegl Lek. 2002;59 Suppl 1:21-4. (In Polish).; Schlössser R.L., Veldman A., Fischer D. et al. Lavage with exogenous surfactant in neonatal meconium aspiration syndrome. Z Geburtshilfe Neonatol. 2002;206(1):15-8. (In German). https://doi.org/10.1055/s-2002-20945.; Wiswell T.E., Knight G.R., Finer N.N. et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics. 2002;109(6):1081-7. https://doi.org/10.1542/peds.109.6.1081.; Chang H.Y., Hsu C.H., Kao H.A. et al. Treatment of severe meconium aspiration syndrome with dilute surfactant lavage. J Formos Med Assoc. 2003;102(5):326-30.; Salvia-Roigés M.D., Carbonell-Estrany X., Figueras-Aloy J., Rodríguez-Miguélez J.M. Efficacy of three treatment schedules in severe meconium aspiration syndrome. Acta Paediatr. 2004;93(1):60-5.; Dargaville P.A., Mills J.F., Copnell B. et al. Therapeutic lung lavage in meconium aspiration syndrome: a preliminary report. J Paediatr Child Health. 2007;43(7-8):539-45. https://doi.org/10.1111/j.1440-1754.2007.01130.x.; Lee S.M., Kim H.M., Jeon J.H. et al. Effect of surfactant lavage in severe Meconium Aspiration Syndrome. Korean J Pediatr. 2008;51:367-71.; Gu H.R. Effect of pig surfactant lung lavage on severe meconium aspiration syndrome. Xian Dai Zhen DuanYu Zhi Liao. 2018;29:719-20. (In Chinese}.; Bandiya P., Nangia S., Saili A. Surfactant lung lavage vs. standard care in the treatment of meconium aspiration syndrome - a randomized trial. J Trop Pediatr. 2019;65(2):114-21. https://doi.org/10.1093/tropej/fmy024.; Jeng M.J., Soong W.J., Lee Y.S. Effective lavage volume of diluted surfactant improves the outcome of meconium aspiration syndrome in newborn piglets. Pediatr Res. 2009;66(1):107-12. https://doi.org/10.1203/PDR.0b013e3181a29092.; Hung H.Y., Jim W.T., Hsu C.H. et al. Small versus large volume dilute surfactant lavage for meconium aspiration syndrome. Acta Paediatr Taiwan. 2006;47(4):181-6.; Клинические рекомендации - Бронхолегочная дисплазия (у детей) - 2024-2025-2026 (05.06.2024). М.: Министерство здравоохранения Российской Федерации, 2024. 60 с. Режим доступа: http://disuria.ru/_ld/14/1425_kr24P27p1MZ.pdf. [Дата обращения: 09.05.2024].; Xiong J., Zhang L., Bao L. Complications and mortality of venovenous extracorporeal membrane oxygenation in the treatment of neonatal respiratory failure: a systematic review and meta-analysis. BMC Pulm Med. 2020;20(1):124. https://doi.org/10.1186/s12890-020-1144-8.; Geyer M., Gohrbandt B., Sagoschen I. et al. Pitfalls of cannulation for extracorporeal life support: review of the literature and illustrative case presentation. J Artif Organs. 2018;21(1):8-16. https://doi.org/10.1007/s10047-017-1004-3.; El Shahed A.I., Dargaville P.A., Ohlsson A., Soll R. Surfactant for meconium aspiration syndrome in term and late preterm infants. Cochrane Database Syst Rev. 2014;2014(12):CD002054. https://doi.org/10.1002/14651858.CD002054.pub3.; Janssen D.J., Carnielli V.P., Cogo P. et al. Surfactant phosphatidylcholine metabolism in neonates with meconium aspiration syndrome. J Pediatr. 2006;149(5):634-9. https://doi.org/10.1016/j.jpeds.2006.07.027.; Dargaville P.A., Mills J.F. Surfactant therapy for meconium aspiration syndrome: current status. Drugs. 2005;65(18):2569-91. https://doi.org/10.2165/00003495-200565180-00003.; Lo C.W., Jeng M.J., Chang F.Y. et al. Therapeutic lung lavage with diluted surfactant in neonates with severe meconium aspiration syndrome. J Chin Med Assoc. 2008;71(2):103-9. https://doi.org/10.1016/S1726-4901(08)70084-4.; Terasaka D., Clark D.A., Singh B.N., Rokahr J. Free fatty acids of human meconium. Biol Neonate. 1986;50(1):16-20. https://doi.org/10.1159/000242556.; Розенберг О.А. Лёгочный сурфактант и его применение при заболеваниях лёгких. Общая реаниматология. 2007;3(1):66-77. https://doi.org/10.15360/1813-9779-2007-1-66-77.; Мостовой А.В., Карпова А.Л., Межинский С.С., Володин Н.Н. Влияние различных концентраций порактанта альфа с одинаковой дозой на исходы у недоношенных новорожденных менее 32 недель. Акушерство, Гинекология и Репродукция. 2023;17(5):565—583. (In English). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.448.; van der Bleek J., Plotz F.B., van Overbeek F.M. et al. Distribution of exogenous surfactant in rabbits with severe respiratory failure: the effect of volume. Pediatr Res. 1993;34(2):154-8. https://doi.org/10.1203/00006450-199308000-00009.; Lista G., Bianchi S., Castoldi F. et al. Bronchoalveolar lavage with diluted porcine surfactant in mechanically ventilated term infants with meconium aspiration syndrome. Clin Drug Investig. 2006;26(1):13-9. https://doi.org/10.2165/00044011-200626010-00002.; Lejeune T., Pfister R.E. Surfactant lavage for extracorporeal membrane oxygenation-requiring meconium aspiration syndrome - a cheap alternative. Eur J Pediatr. 2005;164(5):331-3. https://doi.org/10.1007/s00431-005-1624-0.; Dargaville P.A., Copnell B., Tingay D.G. et al. Refining the method of therapeutic lung lavage in meconium aspiration syndrome. Neonatology. 2008;94(3):160-3. https://doi.org/10.1159/000143394.; https://www.gynecology.su/jour/article/view/2114